2:59 PM
 | 
Nov 14, 2017
 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Frontotemporal dementia

Cell culture and mouse studies suggest inhibiting proteolytic processing of CDK5R1 into its truncated form could help treat frontotemporal dementia (FTD). In FTD patient-derived cerebral organoids, knock-in of a non-cleavable variant...

Read the full 145 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$18 USD
More Info >